The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study.

Autor:	Manea E; National Institute for Infectious Diseases 'Prof. Dr. Matei Bals', Bucharest, Romania; University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania., Sojo-Dorado J; Unidad de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen Macarena / Universidad de Sevilla / Instituto de Biomedicina de Sevilla, Seville, Spain., Jipa RE; National Institute for Infectious Diseases 'Prof. Dr. Matei Bals', Bucharest, Romania; University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania., Benea SN; National Institute for Infectious Diseases 'Prof. Dr. Matei Bals', Bucharest, Romania; University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania., Rodríguez-Baño J; Unidad de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen Macarena / Universidad de Sevilla / Instituto de Biomedicina de Sevilla, Seville, Spain., Hristea A; National Institute for Infectious Diseases 'Prof. Dr. Matei Bals', Bucharest, Romania; University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania. Electronic address: adriana_hristea@yahoo.com.
Jazyk:	angličtina
Zdroj:	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2018 Feb; Vol. 24 (2), pp. 180-184. Date of Electronic Publication: 2017 Jun 19.
DOI:	10.1016/j.cmi.2017.06.005
Abstrakt:	Objective: We aimed to compare the outcomes of patients with C.difficile infection (CDI) treated either with tigecycline associated with vancomycin, or with vancomycin alone. Methods: This single-centre retrospective cohort study included all adults hospitalized from September 2014 through August 2015 for symptomatic, incident CDI confirmed by polymerase chain reaction for C. difficile toxin in stools. The primary outcome was the rate of favourable outcome, defined as a composite of clinical response (resolution of symptoms without need for additional CDI therapy) and achieving discharge without CDI-related surgery or intensive care; a secondary outcome was CDI recurrence. We constructed a non-parsimonious logistic regression model to calculate a propensity score (PS) for those receiving tigecycline. Results: In all, 266 patients were included: 62 patients received both vancomycin and tigecycline, and 204 patients received vancomycin alone. The patients from the two groups were similar regarding demographics and comorbidities but patients in the tigecycline group had a more severe CDI. A favourable outcome in the tigecycline group versus the vancomycin group was found in 50/62 (81%) versus 193/204 (95%). We matched patients receiving tigecycline or not according to the PS and 86 patients (43 pairs) could be matched. The OR for favourable outcome with tigecycline in the matched analysis was 0.92 (95% CI 0.60-1.44; p 0.74). The rate of CDI recurrences was 8/62 (13%) in the tigecycline group versus 39/204 (19%) in the vancomycin group (p 0.2). Conclusion: Adding tigecycline to CDI standard therapy did not increase the clinical cure nor reduce the rate of CDI recurrences. (Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu